GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (MEX:TEVA N) » Definitions » 3-Year Share Buyback Ratio

Teva Pharmaceutical Industries (MEX:TEVA N) 3-Year Share Buyback Ratio : -0.90% (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Teva Pharmaceutical Industries 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Teva Pharmaceutical Industries's current 3-Year Share Buyback Ratio was -0.90%.

The historical rank and industry rank for Teva Pharmaceutical Industries's 3-Year Share Buyback Ratio or its related term are showing as below:

MEX:TEVA N' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -12.6   Med: -2.5   Max: 4.6
Current: -0.9

During the past 13 years, Teva Pharmaceutical Industries's highest 3-Year Share Buyback Ratio was 4.60%. The lowest was -12.60%. And the median was -2.50%.

MEX:TEVA N's 3-Year Share Buyback Ratio is ranked better than
59.56% of 675 companies
in the Drug Manufacturers industry
Industry Median: -2.2 vs MEX:TEVA N: -0.90

Competitive Comparison of Teva Pharmaceutical Industries's 3-Year Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries's 3-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's 3-Year Share Buyback Ratio falls into.


;
;

Teva Pharmaceutical Industries 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Teva Pharmaceutical Industries (MEX:TEVA N) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Teva Pharmaceutical Industries 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Teva Pharmaceutical Industries Business Description

Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Teva Pharmaceutical Industries Headlines

No Headlines